The remaining authors declare which the study was executed in the absence of any business or economical relationships which could be construed as a possible conflict of interest. Inhibition of galectin-three with GB1211 was not relevant to any cure- or dose-similar traits and there have been no clinically significant safety https://codyrepen.onzeblog.com/39447224/the-best-side-of-gb1211